FTSE 100 close: London markets round off the week in the green as US economy impresses again FTSE 100 London markets recorded one of their best days in months as investors were buoyed by a strong jobs report from the US suggesting its a long way off recession. The capital’s premier index climbed 1.46 per cent to 7,599.29 points, while the domestically-focused mid-cap FTSE 250 index, which is more aligned with the health of [...]
Dechra sets sights on expansion with two major deals and South Korean subsidiary veterinary pharma Veterinary business Dechra has its sights set on expansion after setting up a new subsidiary in South Korea and injecting nearly £400m on acquisitions this summer alone. “We have continued to progress on all aspects of our strategy; the product development pipeline was strengthened, material acquisitions were completed post year-end and a new subsidiary was [...]
Dechra wins over US vet group with £220m bid after years of courting pharmaceuticals Veterinary pharmaceutical firm Dechra has splashed more than £220m on an American medicine manufacturer, a long-term acquisition target for the company. Californian Med-Pharmex, which has a workforce of some 130, is expected to bolster Dechra’s manufacturing facilities in North America and provide “attractive financial returns”. The deal will be funded from existing debt resources, London-listed [...]
Dechra Pharmaceuticals hikes dividend but braces itself for no-deal Brexit September 2, 2019 Veterinary drugs maker Dechra Pharmaceuticals has steeled itself for a possible no-deal Brexit by shifting ownership of UK marketing authorisations to a new arm in the Netherlands. Dechra has also moved all its analytical testing methods for products created at its Skipton site in the UK to a new laboratory in Zagreb, Croatia as well [...]
Pet vaccine company Dechra reveals ‘strong’ trading as revenues rise January 14, 2019 Veterinary drugmaker Dechra Pharmaceuticals today credited "strong" trading for an 18 per cent rise in revenue in the six months to 31 December. Both European and North American pharma sales grew by 18 per cent over the period, the firm said in the update. The FTSE 250 company added that it expected its Brexit contingency preparations [...]